Intravitreal Ranibizumab in Recurrent ROP
- Sponsor
- Ameera Gamal Abdelhameed
- Study ID
- NCT04539106
- Status
- Completed
Conditions
- Retinopathy of Prematurity
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- intravitreal injection of Ranibizumab — DRUGintravitreal injection of 0.25 mg/0.025 ml ranibizumab with a 30-gauge needle 1.5mm from limbus
Study Details
A retrospective study included reviewing of medical records of preterm babies who were admitted in neonatal intensive care unit (NICU) of Mansoura University children hospital (MUCH) or referred from nearby hospitals for ROP screening during the period from March 2013 to February 2020.
Key Dates
- First listed
- Sep 4, 2020
- Start date
- Jun 1, 2019
- Status verified
- Aug 2020
- Primary completion
- Feb 1, 2020
- Completion
- Feb 1, 2020
Study Design
- Enrollment
- 115 participants (actual)
Primary Outcome Measure
full vascularization of the retina [ Time Frame: 6 months ]
Related Studies
- Clinical and Genetic Analysis of ROPRecruiting · Oregon Health and Science University · Palo Alto, California
- Retinal Microanatomy in Retinopathy of Prematurity (BabySTEPS2)Recruiting · Duke University · Durham, North Carolina
- Imaging Retinal Vasculature in Infant EyesRecruiting · Duke University · Durham, North Carolina